Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

13

Total facilities

2

Total PLWH

4

Women

23.1%

Children below 5

7.7%

Total deaths

0

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 13 30.8% 4 / 13
Hypertension 13 7.7% 1 / 13
Current new STI (Sexually Transmitted Infection) diagnosis? 13 7.7% 1 / 13
Syphilis 1 100.0% 1 / 1
Chronic heart disease 13 0.0% 0 / 13
Chronic lung disease 13 0.0% 0 / 13
Chronic kidney disease 13 0.0% 0 / 13
Chronic liver disease 13 0.0% 0 / 13
Chronic neurologic condition 13 0.0% 0 / 13
Current alcohol use disorder 13 0.0% 0 / 13
Previous COVID-19 infection 13 0.0% 0 / 13
Diabetes 13 0.0% 0 / 13
Currently smokes tobacco 13 0.0% 0 / 13
Skin Conditions 13 0.0% 0 / 13
Tuberculosis (previous) 13 0.0% 0 / 13
Tuberculosis (active) 13 0.0% 0 / 13
Asplenia 13 0.0% 0 / 13
Cancer 13 0.0% 0 / 13
Immunosuppressive condition 13 0.0% 0 / 13
N. gonorrhoeae 1 0.0% 0 / 1
HSV 1 0.0% 0 / 1
Chlamydia trachomatis 1 0.0% 0 / 1
HPV 1 0.0% 0 / 1
AIDS - defining illness 3 0.0% 0 / 3

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 9 55.6% 5 / 9
Bacteraemia 9 33.3% 3 / 9
Bacterial Pneumonia 9 22.2% 2 / 9
Anaemia 9 11.1% 1 / 9
Sepsis 9 0.0% 0 / 9
Shock 9 0.0% 0 / 9
Seizure 9 0.0% 0 / 9
Encephalitis / Meningitis 9 0.0% 0 / 9
Bleeding Disorder 9 0.0% 0 / 9
Stroke / Cerebrovascular Accident 9 0.0% 0 / 9
Guillain-Barré Syndrome 9 0.0% 0 / 9
Cardiac Arrest 9 0.0% 0 / 9
Cardiac Arrhythmia 9 0.0% 0 / 9
Cardiomyopathy 9 0.0% 0 / 9
Myocarditis / Pericarditis 9 0.0% 0 / 9
Viral Pneumonia / Pneumonitis 9 0.0% 0 / 9
Acute Respiratory Distress Syndrome (Ards) 9 0.0% 0 / 9
Acute Renal Injury / Acute Renal Failure 9 0.0% 0 / 9
Pancreatitis 9 0.0% 0 / 9
Liver Dysfunction 9 0.0% 0 / 9
Urinary Retention 9 0.0% 0 / 9
Ocular Complications 9 0.0% 0 / 9
Necrotizing Infection 9 0.0% 0 / 9
Abscess 9 0.0% 0 / 9
Proctitis 9 0.0% 0 / 9
Rectal Urgency 9 0.0% 0 / 9
Rectal Pain 9 0.0% 0 / 9

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Chest and abdomen 12 100.0% 12/12
Upper limb 12 100.0% 12/12
Head and neck 12 91.7% 11/12
Back 12 91.7% 11/12
Lower limb 12 91.7% 11/12
Mouth 12 58.3% 7/12
Genitals 12 50.0% 6/12

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 13 92.3% 12/13
Umbilicated pustule 13 69.2% 9/13
Early vesicle 13 53.8% 7/13
Small pustule 13 38.5% 5/13
Crusting of a mature lesion 13 38.5% 5/13
Macule 13 30.8% 4/13
Ulcerated lesion 13 23.1% 3/13
Partially removed scab 13 7.7% 1/13

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Muscle pain or aching 13 76.9% 10 / 13
Fatigue or malaise 13 69.2% 9 / 13
Sore throat 13 53.8% 7 / 13
Pain in mouth 13 53.8% 7 / 13
Headache 13 46.2% 6 / 13
Swallowing problem 13 46.2% 6 / 13
Painful swallow 6 83.3% 5 / 6
Joint pain or aching 13 30.8% 4 / 13
Difficult swallow 6 50.0% 3 / 6
Urinary symptoms 13 15.4% 2 / 13
Psychologic disturbance 13 15.4% 2 / 13
Pain with urination 2 100.0% 2 / 2
Ocular symptoms (pain, redness, visual loss) 13 0.0% 0 / 13
Nausea 13 0.0% 0 / 13
Vomiting 13 0.0% 0 / 13
Diarrhoea 13 0.0% 0 / 13
Any rectal symptom 13 0.0% 0 / 13
Chest pain 13 0.0% 0 / 13
Proctitis 13 0.0% 0 / 13
Dizziness 13 0.0% 0 / 13
Decrease urine output 2 0.0% 0 / 2
Urethral discharge 2 0.0% 0 / 2

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 9 0.0% 0 / 9
Muscle pain or aching 9 0.0% 0 / 9
Headache 9 0.0% 0 / 9
Ocular symptoms (pain, redness, visual loss) 9 0.0% 0 / 9
Fatigue or malaise 9 0.0% 0 / 9
Pain in mouth 9 0.0% 0 / 9
Nausea 9 0.0% 0 / 9
Vomiting 9 0.0% 0 / 9
Diarrhoea 9 0.0% 0 / 9
Any rectal symptom 9 0.0% 0 / 9
Swallowing problem 9 0.0% 0 / 9
Chest pain 9 0.0% 0 / 9
Joint pain or aching 9 0.0% 0 / 9
Proctitis 9 0.0% 0 / 9
Dizziness 9 0.0% 0 / 9
Psychologic disturbance 9 0.0% 0 / 9
Urinary symptoms 9 0.0% 0 / 9

Source: WHO
Variable

Person with HIV
N = 4

Person without HIV
N = 9

 p-value 1
age, Median (Q1, Q3) 12.00 (6.00, 12.00) 8.00 (6.00, 9.00) 0.3
    Missing/Unknown 1 0
Sex at birth, n (%)

0.2
    Male 3 (75%) 6 (67%)
    Female 0 (0%) 3 (33%)
    Intersex 0 (0%) 0 (0%)
    Unknown 1 (25%) 0 (0%)
Race, n (%)

0.3
    African/Black 3 (75%) 9 (100%)
    Arab 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%)
    Unknown 1 (25%) 0 (0%)
    Other 0 (0%) 0 (0%)
health care worker, n (%)

0.3
    Yes 0 (0%) 0 (0%)
    No 3 (75%) 9 (100%)
    Unknown 1 (25%) 0 (0%)
Laboratory worker, n (%)

0.3
    Yes 0 (0%) 0 (0%)
    No 3 (75%) 9 (100%)
    Unknown 1 (25%) 0 (0%)
Sex worker, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (75%) 8 (89%)
    Unknown 1 (25%) 1 (11%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


    Yes 0 (NA%) 0 (0%)
    No 0 (NA%) 3 (100%)
    Unknown 0 (NA%) 0 (0%)
    Missing/Unknown 4 6
Breastfeeding, n (%)


    Yes 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%)
    Missing/Unknown 4 9
1

Wilcoxon rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 4

Person without HIV
N = 9

 p-value 1
ever hospitalized, n (%)

>0.9
    Yes 3 (100%) 5 (83%)
    No 0 (0%) 1 (17%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
Length of hospitalization, Median (Q1, Q3) 12 (12, 21) 10 (7, 11) 0.13
    Missing/Unknown 1 4
Escalation of care, n (%)

0.4
    Yes 1 (33%) 0 (0%)
    No 2 (67%) 5 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 4
supplemental oxygen, n (%)

0.4
    Yes 1 (33%) 0 (0%)
    No 2 (67%) 5 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 4
receive nasogastric fluids, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (100%) 6 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
receive IV fluids during course monkeypox infection, n (%)

0.3
    Yes 1 (33%) 0 (0%)
    No 2 (67%) 6 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
receive analgesia for pain management, n (%)

0.5
    Yes 3 (100%) 4 (67%)
    No 0 (0%) 2 (33%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
receive antibiotics during course monkeypox infection, n (%)

>0.9
    Yes 3 (100%) 6 (100%)
    No 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
receive antifungals during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (100%) 6 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
experimental antiviral during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (100%) 6 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 1 3
1

Fisher’s exact test; Wilcoxon rank sum test
Variable

Person with HIV
N = 4

Person without HIV
N = 9

 p-value 1
History of tetanus vaccination, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 1 (25%) 4 (44%)
    Unknown 3 (75%) 5 (56%)
History of smallpox vaccination before 1980, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (75%) 6 (67%)
    Unknown 1 (25%) 3 (33%)
History of smallpox or monkeypox vaccination in past year, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 3 (75%) 7 (78%)
    Unknown 1 (25%) 2 (22%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 4 9
1

Fisher’s exact test
Variable

Person with HIV
N = 4

Person without HIV
N = 9

 p-value 1
New diagnosis of HIV, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 2 (100%) 6 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 2 3
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)


    Yes 0 (0%) 0 (NA%)
    No 1 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%)
    Missing/Unknown 3 9
Immunosuppressive condition, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 4 (100%) 9 (100%)
    Unknown 0 (0%) 0 (0%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA)
    Missing/Unknown 1 9
Viral load, n (%)


    Detectable 0 (0%) 0 (NA%)
    Undetectable 1 (33%) 0 (NA%)
    Unknown 2 (67%) 0 (NA%)
    Missing/Unknown 1 9
AIDS - defining illness, n (%)


    Yes 0 (0%) 0 (NA%)
    No 3 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%)
    Missing/Unknown 1 9
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 13 46.2% 6/13
Number of heterosexual partners in the last three months 6 100.0% 6/6
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 13 7.7% 1/13
International travel within ≤ 21 days prior to symptom onset? 13 0.0% 0/13
Contact with possible animal source within ≤ 21 days prior to symptom onset? 13 0.0% 0/13
Did the patient receive experimental antiviral during course monkeypox infection? 9 0.0% 0/9

Source: WHO
MPOX diagnosis
Variable N = 29
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 9 (100%)
    Unknown 0 (0%)
    Missing/Unknown 20
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 29
Monkeypox PCR, n (%)
    Yes 9 (100%)
    No 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 20
Monkeypox Result, n (%)
    Positive 3 (33%)
    Negative 5 (56%)
    Indeterminate 0 (0%)
    Unknown 1 (11%)
    Missing/Unknown 20
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 9 (100%)
    Unknown 0 (0%)
    Missing/Unknown 20
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 29
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 9 (100%)
    Unknown 0 (0%)
    Missing/Unknown 20
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 29
admission
Variable

admission
N = 29

discharge
N = 29

 p-value 1
Hemoglobin, Median (Q1, Q3) 13.0 (11.1, 17.6) 13.0 (11.1, 17.6) >0.9
WCC total, Median (Q1, Q3) 11 (7, 11) 11 (7, 11) >0.9
Platelets, Median (Q1, Q3) 282 (256, 332) 282 (256, 332) >0.9
PT, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
1

Wilcoxon rank sum test
admission advanced
Variables Lab measures distribution
N Mean Median Min Max Distribution
admission
Hemoglobin 5.00 13.12 13.00 6.30 17.60
Platelets 5.00 351.20 282.00 155.00 731.00
WCC total 5.00 12.26 11.10 3.40 29.00
Antibiotics